Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three
Offerings Grossed $275m And $140m, Respectively
Public Company Edition: A three-per-month IPO pace would top the 25 first-time biopharma offerings in 2024. Also, Akero grossed $402.5m and 89bio raised $250m in follow-on offerings that cashed in on Akero’s Phase IIb MASH readout. Immunovant raised $450m in a private placement.
